New drug combination before stem cell transplant for high-risk blood cancer
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new drug combination (SHR2554 plus azacitidine) given before a stem cell transplant to treat aggressive leukemia, myelodysplastic syndrome, or lymphoblastic leukemia. The goal is to reduce cancer cells before transplant and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 15–60 years old
- Diagnosed with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic neoplasms (MDS), or T-cell leukemia that is high-risk or has come back after treatment
- Have an HLA-matched donor available for stem cell transplant (usually a sibling or matched unrelated donor)
- Good overall health status (able to walk and care for yourself with minimal assistance)
- Heart, lung, liver, and kidney function within acceptable ranges
- Never had a prior stem cell transplant or treatment with an EZH2 inhibitor drug
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination (SHR2554 and azacitidine) given before a stem cell transplant to treat aggressive leukemias, lymphomas, or bone marrow disorders. The goal is to improve survival and reduce cancer recurrence in patients with high-risk or hard-to-treat disease.
This trial tests a combination of three drugs (venetoclax, azacitidine, and homoharringtonine) followed by a donor stem cell transplant for people with intermediate- or high-risk acute myeloid leukemia (AML). The goal is to see if this approach can improve outcomes for patients who have not been treated before.
This clinical trial tests a new combination of chemotherapy drugs (called TmBU) before a stem cell transplant for people with high-risk or relapsed acute leukemia. The goal is to see if this conditioning regimen works better and is safe for patients who need a transplant.
This trial tests whether two drugs—ruxolitinib (a JAK inhibitor) and azacitidine (a low-dose chemotherapy)—can help prevent acute myeloid leukemia from coming back after you receive a stem cell transplant from an unrelated donor. The transplant uses a gentler conditioning approach to reduce side effects while fighting the cancer.
This trial tests a targeted radiation drug (Astatine-211) given before a donor stem cell transplant for people with high-risk leukemia or certain bone-marrow cancers. The goal is to better control the cancer before the transplant.
This trial tests a strong chemotherapy and radiation combo followed by a donor stem cell transplant for people with aggressive blood cancers (like AML or MDS) that haven't responded to earlier treatments or came back. It aims to help prevent the cancer from returning.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.